Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.91 USD
Change Today +0.005 / 0.56%
Volume 18.4K
IMSC On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

implant sciences corp (IMSC) Snapshot

Open
$0.88
Previous Close
$0.90
Day High
$0.92
Day Low
$0.88
52 Week High
09/11/14 - $1.82
52 Week Low
02/18/15 - $0.71
Market Cap
66.4M
Average Volume 10 Days
109.0K
EPS TTM
$-0.34
Shares Outstanding
73.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPLANT SCIENCES CORP (IMSC)

Related News

No related news articles were found.

implant sciences corp (IMSC) Related Businessweek News

No Related Businessweek News Found

implant sciences corp (IMSC) Details

Implant Sciences Corporation, together with its subsidiaries, develops, manufactures, and sells sensors and systems for the security, safety, and defense industries primarily in the United States and internationally. Its products include Quantum Sniffer QS-H150 portable explosives detector for the simultaneous detection of explosives particulates and vapors with or without physical contact and in real-time; and Quantum Sniffer QS-B220 desktop explosives and narcotics detector for the detection and identification of various military, commercial, and improvised explosives, as well as narcotics. Implant Sciences offers its products for use in aviation and transportation security, high threat facilities and infrastructure, military installations, customs and border protection, and mail and cargo screening. The company markets and sells its products through direct sales and marketing staff, as well as through a network of independent and specialized sales representatives, and distributors. Implant Sciences Corporation was founded in 1984 and is headquartered in Wilmington, Massachusetts.

74 Employees
Last Reported Date: 09/29/14
Founded in 1984

implant sciences corp (IMSC) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $270.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $230.0K
Vice President of Technology
Total Annual Compensation: $200.0K
Vice President of Sales & Marketing
Total Annual Compensation: $245.0K
Compensation as of Fiscal Year 2014.

implant sciences corp (IMSC) Key Developments

Implant Sciences Corp. Ships $750,000 of Explosives Trace Detector Systems to Asia

Implant Sciences Corp. reported the shipment of more than $750,000 in explosives trace detection systems to various customers in Asia. The shipments include a mixture of QS-H150 and QS-B220 systems, and will be deployed in military, aviation security, and critical infrastructure protection applications. The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

Implant Sciences Extends Credit Agreements with DMRJ Group, LLC

Implant Sciences Corp. announced the extension of its March 2014 secured credit agreements with DMRJ Group, LLC and the group of investors represented by BAM Administrative Services, LLC. DMRJ has agreed to extend the maturity of all Implant Sciences indebtedness held by DMRJ from March 31, 2015 to March 31, 2016. No other terms or conditions of the DMRJ credit agreements were changed. The maturity of the BAM note has been extended from March 31, 2015 to March 31, 2017. As of April 1, 2015, in consideration of the two year extension, the interest rate on the BAM note will increase by 1%. The remaining terms and conditions of the BAM credit agreement remain the same.

Implant Sciences Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014

Implant Sciences Corp. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, revenues were $2,141,000 against $3,150,00 a year ago. The decrease in revenue is due primarily to: a 31.6% decrease in the number of QS-B220 desktop units sold in the three months ended December 31, 2014, due to decreased shipments to U.S. air cargo screening facilities in the current three month period and a 3.6% decrease in the average unit sales prices, which resulted in a 34.0% decrease in QS-B220 revenues; a 25.0% decrease in the number of QS-H150 handheld units sold, compared to the prior period, due to decreased shipments to Japan and a 15.6% decrease in the average unit sales prices, which resulted in a 36.7% decrease in QS-H150 revenues,  offset partially by a 50.4% increase in sales of parts and supplies. Loss from operation was $4,119,000 against $2,707,000 a year ago. Net loss was $6,244,000 against $4,381,000 a year ago. Net loss per share, basic and diluted was $0.09 against $0.07 a year ago. Adjusted LBITDA was $3,515,000 against $1,891,000 a year ago. The increase in the net loss is primarily due to costs incurred due to the resignation of former CEO, decreased sales and gross margin and an increase in interest expense. For the six months, revenues were $4,010,000 against $4,315,00 a year ago. Loss from operation was $7,460,000 against $7,133,000 a year ago. Net loss was $11,619,000 against $10,402,000 a year ago. Net loss per share, basic and diluted was $0.17 against $0.18 a year ago. Adjusted LBITDA was $5,843,000 against $4,598,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMSC:US $0.91 USD +0.005

IMSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bruker Corp $18.30 USD +0.05
CR Bard Inc $167.71 USD +1.05
Safran SA €64.15 EUR -0.11
Thermo Fisher Scientific Inc $133.69 USD +0.62
View Industry Companies
 

Industry Analysis

IMSC

Industry Average

Valuation IMSC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPLANT SCIENCES CORP, please visit www.implantsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.